Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjogren's Syndrome.

Finally, there was a trend towards increased LILRA3 serum levels in medium/high risk SS patients compared to low risk, though the difference did not reach statistical significance (low risk: 0.40 ± 0.42 ng/mL, medium/high risk: 0.70 ± 0.85 ng/mL) ( Supplementary Figure S2 ). 3.3.

also in 111,027 other papers